Figure 3From: Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center studyOS on the basis of the number of tumor molecular alterations. A significant difference (p < 0.001) was observed among patients harboring no (13.9 months), one (7.3 months) or two (6.4 months) alterations.Back to article page